David Gordon Biography and Net Worth

Insider of Aclaris Therapeutics

David is a physician with over 20 years of pharmaceutical industry experience. Prior to joining Aclaris, he was Senior Vice President and Head of Dermatology Research and Development at GlaxoSmithKline plc. With over 18 years at GlaxoSmithKline plc, he led teams responsible for all stages of research from drug discovery through development and post-approval. He served as Clinical Vice President and Medicine Development Leader in the immuno-inflammation and biopharmaceutical groups at GlaxoSmithKline plc. His experience includes successfully developing and achieving regulatory approval for drugs in a range of therapeutic areas. He received his British medical degree (MB ChB) and Bachelor of Medical Biology from Aberdeen University. He received a Diploma in Anaesthetics from the Faculty of The Royal College of Anaesthetists, London. He is accredited as a specialist in pharmaceutical medicine by the Faculty of Pharmaceutical Medicine in London and is a Fellow of the Faculty (FFPM).

What is David N. Gordon's net worth?: The estimated net worth of David N. Gordon is at least $401,055.84 as of July 13th, 2021. Dr. Gordon owns 147,447 shares of Aclaris Therapeutics stock worth more than $401,056 as of December 22nd. This net worth approximation does not reflect any other investments that Dr. Gordon may own. Learn More about David N. Gordon's net worth.
How do I contact David N. Gordon?: The corporate mailing address for Dr. Gordon and other Aclaris Therapeutics executives is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. Aclaris Therapeutics can also be reached via phone at (484) 324-7933 and via email at [email protected]. Learn More on David N. Gordon's contact information.
Has David N. Gordon been buying or selling shares of Aclaris Therapeutics?: David N. Gordon has not been actively trading shares of Aclaris Therapeutics in the last ninety days. Most recently, David N. Gordon sold 2,631 shares of the business's stock in a transaction on Tuesday, July 13th. The shares were sold at an average price of $16.98, for a transaction totalling $44,674.38. Following the completion of the sale, the insider now directly owns 147,447 shares of the company's stock, valued at $2,503,650.06. Learn More on David N. Gordon's trading history.
Who are Aclaris Therapeutics' active insiders?: Aclaris Therapeutics' insider roster includes Kamil Ali-Jackson (Insider), David Gordon (Insider), Joseph Monahan (Insider), Frank Ruffo (CFO), and Neal Walker (CEO). Learn More on Aclaris Therapeutics' active insiders.
Are insiders buying or selling shares of Aclaris Therapeutics?: During the last year, Aclaris Therapeutics insiders bought shares 11 times. They purchased a total of 3,275,789 shares worth more than $4,476,644.42. The most recent insider tranaction occured on November, 19th when Director Anand Mehra bought 666,666 shares worth more than $1,499,998.50. Insiders at Aclaris Therapeutics own 6.4% of the company. Learn More about insider trades at Aclaris Therapeutics.
Information on this page was last updated on 11/19/2024.

David N. Gordon Insider Trading History at Aclaris Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/13/2021	Sell	2,631	$16.98	$44,674.38	147,447
6/1/2021	Sell	14,000	$23.01	$322,140.00	195,992

David N. Gordon Buying and Selling Activity at Aclaris Therapeutics

Aclaris Therapeutics Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Today's Range

Now: $2.72

$2.71

$2.90

50 Day Range

MA: $2.72

$1.16

$4.59

2 Week Range

Now: $2.72

$0.86

$5.17

Volume

1,156,340 shs

Average Volume

1,386,809 shs

Market Capitalization

$194.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

⭕ [URGENT] Buy Alert just triggered

From Behind the Markets | Ad

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>